Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. 2012

Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
Servicio de Oncología Médica, Hospital Clínico Virgen de la Victoria, Málaga, Spain. bellapajares@yahoo.es

The adverse effects associated to traditional chemotherapy are well known and broadly studied. In the recent years several tyrosine kinase inhibitors have been approved for cancer treatment and numerous are under investigation. These drugs target specific mutated/overexpressed tyrosin kinase receptors and frecuently their pharmacokinetic/pharmacodinamic behavior is not fully elucidated. These new drugs may interact with non-antineoplastic drugs leading to undesirable adverse effects. In this article, we will discuss different types of drug interactions and briefly review the pharmacokinetics and mechanisms of action of tyrosine kinase inhibitors in clinical use, with a particular emphasis on the risk of the occurrence of such interactions based on currently available scientific evidence.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein

Related Publications

Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
September 2014, The Lancet. Oncology,
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
February 2015, British journal of clinical pharmacology,
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
July 2014, The Lancet. Oncology,
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
July 2022, Zhonghua zhong liu za zhi [Chinese journal of oncology],
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
March 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
October 2020, Cancer chemotherapy and pharmacology,
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
February 2011, Blood,
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
December 2014, Journal of pharmaceutical sciences,
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
January 2020, Drug design, development and therapy,
Bella Pajares, and Esperanza Torres, and José Manuel Trigo, and María Isabel Sáez, and Nuria Ribelles, and Begoña Jiménez, and Emilio Alba
January 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Copied contents to your clipboard!